FDA Suspends License for Chikungunya Vaccine

The regulatory agency said it believes that the ‘vaccine is not safe and that continued administration to the public would pose a danger to health.’

A laboratory technician holds a mosquito at the World Mosquito Program factory in Medellín, Colombia, on June 4, 2024. Jaime Saldarriaga/AFP via Getty Images

The Food and Drug Administration (FDA) on Aug. 25 stated that it has suspended approval for a vaccine against chikungunya, a mosquito-borne virus.

Because of reports of serious adverse events following administration of the vaccine, the FDA’s Center for Biologics Evaluation and Research (CBER) “believes [the] vaccine is not safe and that continued administration to the public would pose a danger to health,” the FDA said in a statement.